Agreement adds a new preclinical ADC with potential for enhanced anti-tumour activity and best-in-class profile
Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose
Telangana aims to increase the value of the Life Sciences economy from US$ 80 billion to US$ 250 billion by 2030
INEOS production of BDO in Germany, which produces a vital ingredient for antibiotics, statins and vitamin B6, is being crushed by a flood of carbon heavy imports and product dumping from the Far East
Glenmark’s Ropivacaine Hydrochloride Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug Naropin Injection of Fresenius Kabi USA
The acquisition centers on ImCheck’s lead Phase I/II program, ICT01, a first-in-class monoclonal antibody targeting BTN3A
XTANDI is the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in this patient population, supporting its earlier use in this setting
The expansion underscores Merck’s commitment to invest more than $70 billion in U.S. research, development and capital projects
Based on these promising results, Johnson & Johnson plans to move the program into a Phase 3 trial to further investigate subcutaneous amivantamab
Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation
Subscribe To Our Newsletter & Stay Updated
